[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634216":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":70,"collaborators":25,"id":73,"slug":25,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":25,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":47,"whyStopped":25,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"National Institute of Cardiovascular Diseases, Pakistan","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group (Adenosine Pre-Medication + Standard Care)","EXPERIMENTAL","Patients will receive intracoronary adenosine prior to primary PCI:\n\nDose: 2 mg for left coronary artery, 1 mg for right coronary artery Dilution: 20 mL normal saline Route: Intracoronary (proximal via guide or distal via device) Purpose: To reduce incidence of slow flow\u002Fno-reflow and improve myocardial perfusion.\n\nOther Names: Adenocard (if needed for registry consistency)",[13,14],"Drug: Adenosine pre-medication","Other: Standard care",{"label":16,"type":6,"description":17,"interventionNames":18},"Control Group (Standard Care Alone)","Patients will undergo primary PCI with standard pharmacological therapy, without adenosine pre-medication.\n\nPurpose: Serve as comparator to evaluate the effect of adenosine pre-medication.",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Adenosine pre-medication","Patients will receive intracoronary adenosine before primary PCI in addition to standard pharmacological therapy:\n\nDose: 2 mg for left coronary artery, 1 mg for right coronary artery Dilution: 20 mL normal saline Route: Intracoronary (proximal via guide catheter or distal via delivery device) Timing: Administered immediately prior to PCI Purpose: To evaluate whether adenosine pre-medication reduces the incidence of slow flow\u002Fno-reflow and improves myocardial perfusion outcomes (TIMI flow grade and Myocardial Blush Grade).",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Standard care","Patients will receive standard pharmacological management during primary PCI without adenosine pre-medication.\n\nPurpose: Serves as the control to assess the effect of adenosine on slow flow\u002Fno-reflow and myocardial perfusion.",[16,9],[31],{"name":32,"affiliation":33,"role":34},"Muhammad Nauman, FCPS","National Institute of Cardiovascular Diseases","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Muhammad Nauman Khan, FCPS","CONTACT","+923453549634","nkhan116@yahoo.com",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},"Khalid Naseeb, FCPS","+923002469284","khalidnaseeb50@gmail.com",[46,62],{"facility":33,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Karachi","Sindh","75510","Pakistan",{"type":53,"coordinates":54},"Point",[55,56],67.0104,24.8608,{"lat":56,"lon":55},[59,61],{"name":37,"role":38,"phone":60,"phoneExt":25,"email":40},"+922199201271",{"name":42,"role":34,"phone":25,"phoneExt":25,"email":25},{"facility":33,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},{"type":53,"coordinates":64},[55,56],{"lat":56,"lon":55},[67],{"name":68,"role":38,"phone":60,"phoneExt":25,"email":69},"Mushkbar Fatima, MBA","mushkbarfatima64@gmail.com",{"type":34,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Dr. Muhammad Nauman Khan","Associate Professor","100634216",false,"NCT07536802","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial","AMPACT","Inclusion Criteria:\n\n* All patients with acute STEMI undergoing primary PCI\n* Patients of either sex, ≥18 years of age.\n\nExclusion Criteria:\n\n* STEMI patients with cardiogenic shock at presentation\n* Patients with heart block\n* Allergy to adenosine\n* Patients refuse to give consent for participation","ALL","18 Years","80 Years",{"count":84,"type":85},1148,"ESTIMATED","INTERVENTIONAL",[88],"PHASE4","Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow\u002Fno-reflow after primary percutaneous coronary intervention.",[91,92,93,94],"ST-Segment Elevation Myocardial Infarction (STEMI)","No-Reflow Phenomenon","Coronary Slow Flow","Acute Myocardial Infarction",[96,97,91,92,93,98],"Adenonsine","Primary Percutaneous Coronary Intervention (Primary PCI)","Myocardial Reperfusion","2026-04-17",{"date":101,"type":102},"2026-04-22","ACTUAL",{"date":104,"type":102},"2025-06-01",{"date":106,"type":85},"2026-12-31",{"name":5,"class":6},2]